Avatrombopag is a first-generation drug

Avatrombopag, also known asAvatrombopag or Sucoxin, is a second-generation thrombopoietin receptor agonist (TPO-RA). This drug has significant innovation and clinical value in the field of platelet production, providing a new treatment option for patients with chronic liver disease (CLD)-related thrombocytopenia and immune thrombocytopenia (ITP) worldwide.

Avatrombopag was approved by the U.S. Food and Drug Administration (FDA) in May 2018 and June 2019 for the treatment of chronic liver disease-related thrombocytopenia and immune thrombocytopenia in patients scheduled for elective diagnostic procedures or surgeries.

The main function of avatrombopag is to stimulate the proliferation and differentiation of megakaryocytes in bone marrow progenitor cells, thereby increasing platelet production. Compared with traditional thrombopoietin-stimulating drugs, avatrombopag is a small molecule non-peptide and does not produce sequence homology or immunogenicity with endogenous thrombopoietin (TPO), so there is no risk of antibody formation. In addition, avatrombopag has a additive platelet-elevating effect, which can maintain platelet counts at safe levels for a longer period of time with a lower potential risk of thrombosis.

Avatrombopag has shown impressive efficacy in clinical studies. In a pivotal Phase III randomized trial, most patients achieved platelet counts of at least 50,000/µL on day 8 of treatment and maintained platelet counts within the target range for 6 months of treatment. In contrast, patients in the placebo group showed no significant improvement in platelet counts. These results demonstrate the significant efficacy of avatrombopag in increasing platelet counts and improving patient condition.

However, despite its clinical efficacy, avatrombopag is not perfect. Some patients may experience side effects such as headache and nasopharyngitis, and some side effects may be serious. In addition, the price of avatrombopag is relatively high, which may put some pressure on patients' financial burden. Therefore, when using avatrombopag, it is necessary to fully consider the individual differences and condition needs of patients, and weigh the efficacy and risks of the drug.

AvatrombopagIt has been approved for marketing in the country and is covered by medical insurance. There are mainly two versions on the market: original research and domestic imitation, each box contains 20mg*15 tablets. After medical insurance, the price of original drugs fluctuates around 4,000 yuan, and the price of domestic generic drugs exceeds 3,000 yuan. However, there are cheaper generic drugs overseas, and 28 tablets only cost about 600 yuan, which is a significant difference.

In summary, avatrombopag, as a new oralTPO receptor agonist, has significant advantages and effects in the treatment of chronic liver disease-related thrombocytopenia and immune thrombocytopenia. With the deepening of research and the promotion of application, it is believed that avatrombopag will bring good news to more patients. At the same time, we also look forward to the emergence of more innovative drugs in the future to provide more choices and better therapeutic effects for clinical treatment.